25370-46-1

Usage

Uses

γ-Pyridyl- and γ-quinolylbutyrolactones as potential anthelmintics.

InChI:InChI=1/C11H13NO3/c1-2-15-11(14)4-3-10(13)9-5-7-12-8-6-9/h5-8H,2-4H2,1H3

Upstream product

• 54109-96-5 diethyl 4-pyridylcarbonylsuccinate 
• 123-25-1 succinic acid diethyl ester 
• 872-85-5 pyridine-4-carbaldehyde 
• 140-88-5 ethyl acrylate 
• 1570-45-2 isonicotinic acid ethylester 
• 55-22-1 pyridine-4-carboxylic acid 

Downstream Products

• 91370-63-7 ethyl 4-(piperidin-4-yl)butyrate 
• 250601-68-4 ethyl 4-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-(4-pyridyl)butyrate 

Relevant academic research and scientific papers

NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION

The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

1-butyl-3-methylimidazolium bromide as a solvent and precatalyst for stetter reaction

Stetter reaction between aromatic aldehydes and acrylonitrile/ethyl acrylate performing in [Bmim]Br in the presence of NaOH is described. N-Heterocyclic carbene (NHC) generates in situ is shown to be an efficient catalyst. Benzoin condensation also occured as side reaction.

Studies on non-thiazolidinedione antidiabetic Agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents

We previously reported that (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl) methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) showed potent glucose and lipid lowering effects in genetically obese and diabetic mice, KKA y. This compound a

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.